Keyword Analysis & Research: apixaban half life in renal impairment

tg.org.au

https://australianprescriber.tg.org.au/articles/apixaban.html

DA: 42 PA: 89 MOZ Rank: 66 Up or Down: Up

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491286/

DA: 89 PA: 55 MOZ Rank: 54 Up or Down: Up

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473496/

WEBJun 12, 2017 · Apixaban . The renal elimination of apixaban is 27%, which is the lowest among the DOACs.44 It is eliminated by oxidative metabolism, renal, and intestinal routes. In the ARISTOTLE trial, patients with a serum creatinine level of 1.5 mg/dL and atrial … Author: Jens Lutz, Kerstin Jurk, Helmut Schinzel Publish Year: 2017

Author: Jens Lutz, Kerstin Jurk, Helmut Schinzel

Publish Year: 2017

DA: 50 PA: 76 MOZ Rank: 63 Up or Down: Up

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473496/table/t1-ijnrd-10-135/

DA: 90 PA: 18 MOZ Rank: 46 Up or Down: Up

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491286/

WEBMar 16, 2017 · Apixaban 2.5 mg twice daily in patients on hemodialysis resulted in drug exposure comparable with that of the standard dose (5 mg twice daily) in patients with … Author: Thomas A Mavrakanas, Caroline Flora Samer, Sharon J Nessim, Gershon Frisch, Mark L Lipman DOI: 10.1681/ASN.2016090980 Publish Year: 2017 Publication: J Am Soc Nephrol. 2017 Jul; 28(7): 2241-2248.

Author: Thomas A Mavrakanas, Caroline Flora Samer, Sharon J Nessim, Gershon Frisch, Mark L Lipman

DOI: 10.1681/ASN.2016090980

Publish Year: 2017

Publication: J Am Soc Nephrol. 2017 Jul; 28(7): 2241-2248.

DA: 100 PA: 50 MOZ Rank: 48 Up or Down: Up

ahajournals.org

https://www.ahajournals.org/doi/full/10.1161/circulationaha.111.084996

WEBIn particular, patients with stage 3 to 4 CKD appeared to gain a larger risk reduction in major bleeding with apixaban over warfarin compared with … Author: Davide Capodanno, Dominick J. Angiolillo Publish Year: 2012

Author: Davide Capodanno, Dominick J. Angiolillo

Publish Year: 2012

DA: 50 PA: 39 MOZ Rank: 18 Up or Down: Up

ahajournals.org

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.036449

WEBOct 8, 2018 · Randomized trials to date of apixaban versus warfarin for AF excluded patients with severe and end-stage kidney disease, calculated creatinine clearance <25 … Author: Elaine M. Hylek Publish Year: 2018

Author: Elaine M. Hylek

Publish Year: 2018

DA: 12 PA: 55 MOZ Rank: 55 Up or Down: Up

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928643/

WEBNov 29, 2022 · Apixaban clearance is less dependent on renal function compared to other direct‐acting oral anticoagulants. Data from retrospective studies suggest that apixaban … DOI: 10.1002/jha2.606 Published: 2023/02 Publication: EJHaem. 2023 Feb; 4(1): 291-293.

DOI: 10.1002/jha2.606

Published: 2023/02

Publication: EJHaem. 2023 Feb; 4(1): 291-293.

DA: 46 PA: 85 MOZ Rank: 98 Up or Down: Up

aafp.org

https://www.aafp.org/pubs/afp/issues/2018/0415/p496.html

WEBApr 15, 2018 · Apixaban (Eliquis) renal dosing was included as 2.5 mg orally twice daily if at least one criterion is met: serum creatinine 1.5 mg per dL (133 μmol per L) or more, age 80 years or older, or...

DA: 38 PA: 45 MOZ Rank: 12 Up or Down: Up

oup.com

https://academic.oup.com/ndt/article/33/10/1683/4682924

WEBDec 1, 2017 · Rivaroxaban (20 mg once a day), edoxaban (60 mg once a day) and apixaban (5 mg twice a day) do not require any dose adjustment in patients with a GFR …

DA: 16 PA: 15 MOZ Rank: 42 Up or Down: Up

ahajournals.org

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065614

WEBSep 8, 2023 · Compared with 2.5 mg, use of 5 mg apixaban was associated with a higher risk of bleeding in patients with atrial fibrillation and severe chronic kidney disease, with …

DA: 95 PA: 1 MOZ Rank: 1 Up or Down: Up

nih.gov

https://pubmed.ncbi.nlm.nih.gov/36803700/

WEBMar 1, 2023 · Renal impairment limits DOAC use. Studies supporting Food and Drug Administration (FDA)-approval for apixaban did not include patients with a creatinine …

DA: 7 PA: 12 MOZ Rank: 73 Up or Down: Up

wiley.com

https://onlinelibrary.wiley.com/doi/10.1002/clc.22591

WEBOct 7, 2016 · Key pharmacokinetic properties of direct oral anticoagulants in special populations 1 1 There are no published pharmacokinetic studies of dabigatran in obesity, …

DA: 39 PA: 36 MOZ Rank: 31 Up or Down: Up